Sequella teams up with PATH & US Agency for International Development on TB (tuberculosis) diagnostic
This article was originally published in Clinica
The start-up company Sequella says it will partner with PATH, a prominent international healthcare non-profit company, in testing the effectiveness of the company's novel tuberculosis diagnostic.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.